Related references
Note: Only part of the references are listed.Role of FGFR3 in bladder cancer: Treatment landscape and future challenges
Claudia Maria Ascione et al.
CANCER TREATMENT REVIEWS (2023)
Biomarkers of response to PD-1 pathway blockade
Hanxiao Li et al.
BRITISH JOURNAL OF CANCER (2022)
Predictive clinico-pathological factors to identify BCG, unresponsive patients, after re-resection for T1 high grade non-muscle invasive bladder cancer
Matteo Ferro et al.
UROLOGIC ONCOLOGY-SEMINARS AND ORIGINAL INVESTIGATIONS (2022)
Th1-Dominant CD4+ T Cells Orchestrate Endogenous Systematic Antitumor Immune Memory After Cryo-Thermal Therapy
Peng Peng et al.
FRONTIERS IN IMMUNOLOGY (2022)
Mass Cytometry Reveals Classical Monocytes, NK Cells, and ICOS+CD4+T Cells Associated with Pembrolizumab Efficacy in Patients with Lung Cancer
Philippe Rochigneux et al.
CLINICAL CANCER RESEARCH (2022)
Systemic CD4 Immunity and PD-L1/PD-1 Blockade Immunotherapy
David Escors et al.
INTERNATIONAL JOURNAL OF MOLECULAR SCIENCES (2022)
Detailed bladder cancer immunoprofiling reveals new clues for immunotherapeutic strategies
Nicole Viveiros et al.
CLINICAL & TRANSLATIONAL IMMUNOLOGY (2022)
PD-L1 expression and pattern of immune cells in pre-treatment specimens are associated with disease-free survival for HR-NMIBC undergoing BCG treatment
Mathieu Roumiguie et al.
WORLD JOURNAL OF UROLOGY (2021)
Global cancer statistics 2020: GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries
Hyuna Sung et al.
CA-A CANCER JOURNAL FOR CLINICIANS (2021)
Adjuvant atezolizumab versus observation in muscle-invasive urothelial carcinoma (IMvigor010): a multicentre, open-label, randomised, phase 3 trial
Joaquim Bellmunt et al.
LANCET ONCOLOGY (2021)
Identification of a Novel Inflamed Tumor Microenvironment Signature as a Predictive Biomarker of Bacillus Calmette-Guerin Immunotherapy in Non-Muscle-Invasive Bladder Cancer
Jeffrey S. Damrauer et al.
CLINICAL CANCER RESEARCH (2021)
CD4 T-Cell Exhaustion: Does It Exist and What Are Its Roles in Cancer?
Alexandra M. Miggelbrink et al.
CLINICAL CANCER RESEARCH (2021)
Identification of Signature Genes Associated With Invasiveness and the Construction of a Prognostic Model That Predicts the Overall Survival of Bladder Cancer
Yang He et al.
FRONTIERS IN GENETICS (2021)
Tumour-associated B cells in urothelial urinary bladder cancer
A. Ali Zirakzadeh et al.
SCANDINAVIAN JOURNAL OF IMMUNOLOGY (2020)
Prognostic significance of pre- and post-treatment PD-L1 expression in patients with primary high-grade non-muscle-invasive bladder cancer treated with BCG immunotherapy
Ahmet Murat Aydin et al.
WORLD JOURNAL OF UROLOGY (2020)
Cytotoxic CD4+ T Cells in Bladder Cancer-A New License to Kill
Adrian G. Sacher et al.
CANCER CELL (2020)
Intratumoral CD4+ T Cells Mediate Anti-tumor Cytotoxicity in Human Bladder Cancer
David Y. Oh et al.
CELL (2020)
Analysis of CXCL9, PD1 and PD-L1 mRNA in Stage T1 Non-Muscle Invasive Bladder Cancer and Their Association with Prognosis
Jennifer Kubon et al.
CANCERS (2020)
Dysregulation of the Immune Microenvironment Contributes to Malignant Progression and Has Prognostic Value in Bladder Cancer
Zongtai Zheng et al.
FRONTIERS IN ONCOLOGY (2020)
Prognostic Role of FGFR3 Expression Status and Tumor-Related MicroRNAs Level in Association with PD-L1 Expression in Primary Luminal Non-Muscular Invasive Bladder Carcinoma
Ekaterina Blinova et al.
LIFE-BASEL (2020)
PD-1 and PD-L1 in cancer immunotherapy: clinical implications and future considerations
Yongshuai Jiang et al.
HUMAN VACCINES & IMMUNOTHERAPEUTICS (2019)
The epidemiology of bacille Calmette-Guerin infections after bladder instillation from 2002 through 2017: a nationwide retrospective cohort study
Emilie S. Larsen et al.
BJU INTERNATIONAL (2019)
Combined assessment of peritumoral Th1/Th2 polarization and peripheral immunity as a new biomarker in the prediction of BCG response in patients with high-risk NMIBC
Roberto Martinez et al.
ONCOIMMUNOLOGY (2019)
Functional systemic CD4 immunity is required for clinical responses to PD-L1/PD-1 blockade therapy
Miren Zuazo et al.
EMBO MOLECULAR MEDICINE (2019)
Tumor immune microenvironment in non-muscle-invasive urothelial carcinoma of the bladder
Marie-Lisa Eich et al.
HUMAN PATHOLOGY (2019)
Clinical efficacy and biomarker analysis of neoadjuvant atezolizumab in operable urothelial carcinoma in the ABACUS trial
Thomas Powles et al.
NATURE MEDICINE (2019)
B cells sustain inflammation and predict response to immune checkpoint blockade in human melanoma
Johannes Griss et al.
NATURE COMMUNICATIONS (2019)
CD4+ T cell help creates memory CD8+ T cells with innate and help-independent recall capacities
Tomasz Ahrends et al.
NATURE COMMUNICATIONS (2019)
Cognate Interaction With CD4+ T Cells Instructs Tumor-Associated Macrophages to Acquire M1-Like Phenotype
David Eisel et al.
FRONTIERS IN IMMUNOLOGY (2019)
The prognostic values of tumor-infiltrating neutrophils, lymphocytes and neutrophil/lymphocyte rates in bladder urothelial cancer
Kangkang Liu et al.
PATHOLOGY RESEARCH AND PRACTICE (2018)
Enhanced expression of PD-L1 in non-muscle-invasive bladder cancer after treatment with Bacillus Calmette-Guerin
Akihito Hashizume et al.
Oncotarget (2018)
Neoadjuvant immune checkpoint blockade in high-risk resectable melanoma
Rodabe N. Amaria et al.
NATURE MEDICINE (2018)
High PDL1 mRNA expression predicts better survival of stage pT1 non-muscle-invasive bladder cancer (NMIBC) patients
Johannes Breyer et al.
CANCER IMMUNOLOGY IMMUNOTHERAPY (2018)
Regulatory T Cells and Tumor-Associated Macrophages in the Tumor Microenvironment in Non-Muscle Invasive Bladder Cancer Treated with Intravesical Bacille Calmette-Guerin: A Long-Term Follow-Up Study of a Japanese Cohort
Makito Miyake et al.
INTERNATIONAL JOURNAL OF MOLECULAR SCIENCES (2017)
Differential Expression of PD-L1 in High Grade T1 vs Muscle Invasive Bladder Carcinoma and its Prognostic Implications
Stephanie A. M. Wankowicz et al.
JOURNAL OF UROLOGY (2017)
Tertiary Lymphoid Structures in Cancer: Drivers of Antitumor immunity, immunosuppression, or Bystander Sentinels in Disease?
Emily Jayne Colbeck et al.
FRONTIERS IN IMMUNOLOGY (2017)
Tertiary Lymphoid Structures Associate with Tumour Stage in Urothelial Bladder Cancer
Madhuri Koti et al.
BLADDER CANCER (2017)
Systemic Immunity Is Required for Effective Cancer Immunotherapy
Matthew H. Spitzer et al.
CELL (2017)
The 2016 WHO Classification of Tumours of the Urinary System and Male Genital Organs-Part A: Renal, Penile, and Testicular Tumours
Holger Moch et al.
EUROPEAN UROLOGY (2016)
T Cell Help Amplifies Innate Signals in CD8+ DCs for Optimal CD8+ T Cell Priming
Marie Greyer et al.
CELL REPORTS (2016)
The multifaceted role of CD4+ T cells in CD8+ T cell memory
Brian J. Laidlaw et al.
NATURE REVIEWS IMMUNOLOGY (2016)
Correlation of tumor-infiltrating lymphocytes with bladder cancer recurrence in patients with solitary low-grade urothelial carcinoma
Kristian Krpina et al.
VIRCHOWS ARCHIV (2015)
Clinicopathological characteristics of urothelial bladder cancer in patients less than 40 years old
Eva Comperat et al.
VIRCHOWS ARCHIV (2015)
Tumor microenvironment B cells increase bladder cancer metastasis via modulation of the IL-8/androgen receptor (AR)/MMPs signals
Zhenyu Ou et al.
ONCOTARGET (2015)
Heterogeneity in the Differentiation and Function of CD8+ T Cells
Hans-Willi Mittruecker et al.
ARCHIVUM IMMUNOLOGIAE ET THERAPIAE EXPERIMENTALIS (2014)
Epidemiology and Risk Factors of Urothelial Bladder Cancer
Maximilian Burger et al.
EUROPEAN UROLOGY (2013)
Regulatory T cells, dendritic cells and neutrophils in patients with renal cell carcinoma
Ivo Minarik et al.
IMMUNOLOGY LETTERS (2013)
Multiplex B Cell Characterization in Blood, Lymph Nodes, and Tumors from Patients with Malignancies
A. Ali Zirakzadeh et al.
JOURNAL OF IMMUNOLOGY (2013)
Safety and Activity of Anti-PD-L1 Antibody in Patients with Advanced Cancer
Julie R. Brahmer et al.
NEW ENGLAND JOURNAL OF MEDICINE (2012)
Safety, Activity, and Immune Correlates of Anti-PD-1 Antibody in Cancer
Suzanne L. Topalian et al.
NEW ENGLAND JOURNAL OF MEDICINE (2012)
Prognostic significance of CD45RO+memory T cells in renal cell carcinoma
K. Hotta et al.
BRITISH JOURNAL OF CANCER (2011)
Macrophage infiltration and its prognostic relevance in clear cell renal cell carcinoma
Yoshihiro Komohara et al.
CANCER SCIENCE (2011)
Angiogenesis in renal cell carcinoma: The role of tumor-associated macrophages
Hiroshi Toge et al.
INTERNATIONAL JOURNAL OF UROLOGY (2009)
Targeting dendritic cell signaling to regulate the response to immunization
David Escors et al.
BLOOD (2008)
Type, density, and location of immune cells within human colorectal tumors predict clinical outcome
Jerom Galon et al.
SCIENCE (2006)
Monoclonal antibodies that identify the CD3 molecules expressed specifically at the surface of porcine γδ-T cells
HZ Yang et al.
IMMUNOLOGY (2005)
Costimulatory B7-H1 in renal cell carcinoma patients: Indicator of tumor aggressiveness and potential therapeutic target
RH Thompson et al.
PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA (2004)
The side effects of Bacillus Calmette-Guerin in the treatment of Ta T1 bladder cancer do not predict its efficacy: Results from a European organisation for research and treatment of cancer genito-urinary group phase III trial
RJ Sylvester et al.
EUROPEAN UROLOGY (2003)
CD4+ T cells are required for secondary expansion and memory in CD8+ T lymphocytes
EM Janssen et al.
NATURE (2003)
Share Paper
